Central Precocious Puberty in a Three-Year-Old Girl

Suryani Jamal, Liong Boy Kurniawan, suci aprianti, Ratna Dewi Artati, Ruland DN Pakasi, R Satriono


Precocious puberty is defined as the onset of secondary sexual characteristics before 8 years of age in girls and 9 years in boys. Central Precocious Puberty (CPP) is caused by early activation of the hypothalamic-pituitary-gonadal axis. Laboratory test of LH, FSH, and Estradiol is recommended for monitoring suppressive effects from GnRHa therapy in the early three months and every six months. This study aimed to report a case of CPP in a 3-year and 3-month-old girl. A 3-year and 3-month-old girl went to the hospital with vaginal bleeding (menstruation), breast development, and pubic and axilla hair for 7-month-old. Physical examination found moderately ill with obesity, body weight 20 kg, height 98 cm. Tanner stage was A2M3P2, café au lait was found in the left forehead with size 7x3.5 cm. In March 2015 before GnRHa therapy, LH, FSH and Estradiol level increased with levels of 4.32 mlU/mL, 6.01 mlU/mL, and 67 pg/mL, and after 3 months of the treatment was 0.87 mlU/mL, 2.51 mlU/mL and <20 pg/mL. Pelvic ultrasonography showed suggestive precocious puberty, bone age 5-year and 9-month (Greulich and Pyle), CT-Scan of the brain showed hypothalamic tumor suspected hypothalamic hamartoma. This patient was treated with a GnRHa injection every 4 weeks. Leuprorelin is a synthetic non-peptide analogue of natural GnRH. The diagnosis was based on medical history, physical examination, laboratory, and radiological findings. The prognosis of the patient was good.


Precocious puberty, central precocious puberty, laboratory monitoring, GnRH agonist

Full Text:



Coal JRL, Tridjaja B, Pulungan AB. Puberty and its

disorders in children. Endocrinology textbook. Issue I.

UKAI Child and Adolescent Endocrinology UKAI, 2015;

: 85-104.

P Pallavee, Samal R. Precocious puberty: A clinical

review. International Journal of Reproduction,

Contraception, Obstetrics and Gynecology, 2018; 7(3):


Kiess W, Hoppmann J, Gesing J, Penke M, Korner A,

et al. Puberty-genes, environment and clinical issues. J

Pediatr Endocrinol Metab, 2016; 29(11): 1229-31.

Guaraldi F, Beccuti G, Gori D, Ghizzoni L. Management

of endocrine disease: Long-term outcomes of the

treatment of central precocious puberty. Eur J

Endocrinol, 2016; 174(3): R79-87.

Latronico AC, Brito VN, Carel JC. Causes, diagnosis,

and treatment of central precocious puberty. Lancet

Diabetes Endocrinol, 2016; 4: 265-274.

Emmanuel M, Bokor BR. Tanner stages. In: StatPearls

(Internet). Treasure Island, StatPearl Publishing, 2020.

Available from: https ://www.ncbi.nlm.nih.

gov/books/NBK470280/2021 (accessed 18 Jan, 2020).

DOI: http://dx.doi.org/10.24293/ijcpml.v27i3.1568


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.